m-1 anti-infective advisory committee march 24, 2000 zyvox ™ (linezolid) pharmacia and upjohn
TRANSCRIPT
![Page 1: M-1 Anti-Infective Advisory Committee March 24, 2000 ZYVOX ™ (linezolid) Pharmacia and Upjohn](https://reader035.vdocuments.us/reader035/viewer/2022062314/56649e225503460f94b0f2b9/html5/thumbnails/1.jpg)
M-1
Anti-Infective Advisory CommitteeAnti-Infective Advisory Committee
March 24, 2000March 24, 2000
ZYVOXZYVOX™™ (linezolid) (linezolid)
Pharmacia and UpjohnPharmacia and Upjohn
![Page 2: M-1 Anti-Infective Advisory Committee March 24, 2000 ZYVOX ™ (linezolid) Pharmacia and Upjohn](https://reader035.vdocuments.us/reader035/viewer/2022062314/56649e225503460f94b0f2b9/html5/thumbnails/2.jpg)
M-2
Pharmacia & Upjohn is Seeking Approval of Linezolid for:
• Nosocomial pneumonia
• Community-acquired pneumonia
• Complicated skin and skin structure infections
• Uncomplicated skin and skin structure infections
• Vancomycin-resistant Enterococcus faecalis and Enterococcus faecium infections
![Page 3: M-1 Anti-Infective Advisory Committee March 24, 2000 ZYVOX ™ (linezolid) Pharmacia and Upjohn](https://reader035.vdocuments.us/reader035/viewer/2022062314/56649e225503460f94b0f2b9/html5/thumbnails/3.jpg)
M-3
Linezolid - Presentation Agenda
Introduction W. Gary Tarpley, PhDMicrobiology VP, Discovery Research
Clinical Pharmacology Barry Hafkin, MDClinical Trial Results Director, Clinical Research
Early Pediatric Studies Donald Anderson, MD CSO, Research & Development
Conclusion W. Gary Tarpley, PhD
![Page 4: M-1 Anti-Infective Advisory Committee March 24, 2000 ZYVOX ™ (linezolid) Pharmacia and Upjohn](https://reader035.vdocuments.us/reader035/viewer/2022062314/56649e225503460f94b0f2b9/html5/thumbnails/4.jpg)
M-4
Most Common Nosocomial Blood Culture Isolates (US Hospitals)
Rank Pathogen (N=12,243) %
1 Coagulase-negative staph 322 S. aureus 163 Enterococcus spp 114 Candida spp 85 E. coli 6
Edmond et al., Clin Infect Dis.1999;29:234-244.
SCOPE Project
![Page 5: M-1 Anti-Infective Advisory Committee March 24, 2000 ZYVOX ™ (linezolid) Pharmacia and Upjohn](https://reader035.vdocuments.us/reader035/viewer/2022062314/56649e225503460f94b0f2b9/html5/thumbnails/5.jpg)
M-5
100
80
60
40
20
0
19801975 1985 1990 1995 20001997
GISAGISA33
VREVRE11
PRSPPRSP22
MRSAMRSA11
MRSEMRSE11
Percentage ofPathogens
Resistant toAntibiotics
Increasing Incidence of Resistance in the USMRSE, MRSA, VRE, PRSP, GISA 1980-1999
1NNIS data2TRUST2 project3MMWR, July 11, 1997
![Page 6: M-1 Anti-Infective Advisory Committee March 24, 2000 ZYVOX ™ (linezolid) Pharmacia and Upjohn](https://reader035.vdocuments.us/reader035/viewer/2022062314/56649e225503460f94b0f2b9/html5/thumbnails/6.jpg)
M-6
Limitations of Current Antibiotics for Serious Gm+ Infections
• Tolerability
• Formulation / route of administration
• Drug resistance
![Page 7: M-1 Anti-Infective Advisory Committee March 24, 2000 ZYVOX ™ (linezolid) Pharmacia and Upjohn](https://reader035.vdocuments.us/reader035/viewer/2022062314/56649e225503460f94b0f2b9/html5/thumbnails/7.jpg)
M-7
New Antibacterials are Required to Treat Gm+ Bacterial Infections
• Novel mechanism of action
• Broad coverage of Gm+ bacteria
• Well-tolerated
• Flexible dosing
![Page 8: M-1 Anti-Infective Advisory Committee March 24, 2000 ZYVOX ™ (linezolid) Pharmacia and Upjohn](https://reader035.vdocuments.us/reader035/viewer/2022062314/56649e225503460f94b0f2b9/html5/thumbnails/8.jpg)
M-8
Linezolid: First Antibacterial from a New Structural Class
N O
O
NH
C
O
CH3
F
NO
H5
Morpholino group enhances pharmacokinetic profile & improves water solubility Strategically located
fluorine atom improves activity
C - 5 acylaminomethyl group essential
5 - (S) - configuration necessary
N - Aryl group required
![Page 9: M-1 Anti-Infective Advisory Committee March 24, 2000 ZYVOX ™ (linezolid) Pharmacia and Upjohn](https://reader035.vdocuments.us/reader035/viewer/2022062314/56649e225503460f94b0f2b9/html5/thumbnails/9.jpg)
M-9
Linezolid Profile
• Synthetic
• Broad Gm+ antibacterial spectrum
– Coverage of drug-sensitive bacteria and bacteria resistant to any other drug class
• Unique Site of Action
– No pre-existing cross resistance
![Page 10: M-1 Anti-Infective Advisory Committee March 24, 2000 ZYVOX ™ (linezolid) Pharmacia and Upjohn](https://reader035.vdocuments.us/reader035/viewer/2022062314/56649e225503460f94b0f2b9/html5/thumbnails/10.jpg)
M-10
Linezolid : Unique Site of Action
Initiation Factors
30S ribosome
mRNA50S
ribosome
30S + mRNA
fMet - tRNA
Elongation Factors
70S Initiation Complex
Peptide Product
Elongation
AminoglycosidesMacrolides Streptogramins
Linezolid blocks formation of the
initiation complex
![Page 11: M-1 Anti-Infective Advisory Committee March 24, 2000 ZYVOX ™ (linezolid) Pharmacia and Upjohn](https://reader035.vdocuments.us/reader035/viewer/2022062314/56649e225503460f94b0f2b9/html5/thumbnails/11.jpg)
M-11
Linezolid Profile (cont.)
• 100% oral bioavailability
• Multiple dosage forms
– Solution for IV
– Tablets and suspension for oral
• IV/oral equivalent dosing
– Equal drug exposures after equal doses independent of formulation/route of administration
![Page 12: M-1 Anti-Infective Advisory Committee March 24, 2000 ZYVOX ™ (linezolid) Pharmacia and Upjohn](https://reader035.vdocuments.us/reader035/viewer/2022062314/56649e225503460f94b0f2b9/html5/thumbnails/12.jpg)
M-12
Efficacy - Phase III Studies in Adults
55* Complicated 33* Inpatient CAP 31 MRSA
39A* Uncomplicated 51* Outpatient CAP 54A* VRE
48A* HAP
* Pivotal trials
Resistant SST Pneumonia Pathogens
![Page 13: M-1 Anti-Infective Advisory Committee March 24, 2000 ZYVOX ™ (linezolid) Pharmacia and Upjohn](https://reader035.vdocuments.us/reader035/viewer/2022062314/56649e225503460f94b0f2b9/html5/thumbnails/13.jpg)
M-13
No. Isolates
Streptococci Staphylococci Enterococci
Preclinical Studies 2,985 4,589 2,169
Sentry Study 630 6,276 1,417 (1998; >30 medical centers)
Phase III Isolates 600 1,738 303
TOTAL 4,215 12,603 3,889
In Vitro Susceptibility Database
![Page 14: M-1 Anti-Infective Advisory Committee March 24, 2000 ZYVOX ™ (linezolid) Pharmacia and Upjohn](https://reader035.vdocuments.us/reader035/viewer/2022062314/56649e225503460f94b0f2b9/html5/thumbnails/14.jpg)
M-14
Streptococci: Preclinical Summary
No. Species Category2 Isolates MIC50 MIC90
S. pneumoniae PSSP 303 0.6 1.0
PISP 242 0.6 1.0
PRSP 266 0.6 0.9
S. pyogenes 181 1.1 2.2
S. agalactiae 164 1.9 2.0
Average1
1 Weighted average calculated for pooled studies.2 NCCLS criteria
![Page 15: M-1 Anti-Infective Advisory Committee March 24, 2000 ZYVOX ™ (linezolid) Pharmacia and Upjohn](https://reader035.vdocuments.us/reader035/viewer/2022062314/56649e225503460f94b0f2b9/html5/thumbnails/15.jpg)
M-15
Sentry (N = 318)
Phase III (N = 346)
Total N = 664
S. pneumoniae Sentry and Phase III Data
Linezolid MIC (µg/mL)
% o
f Iso
late
s
0
20
40
60
80
100
<0.06 .12 .25 .50 1 2 4 8 16 32 >32
![Page 16: M-1 Anti-Infective Advisory Committee March 24, 2000 ZYVOX ™ (linezolid) Pharmacia and Upjohn](https://reader035.vdocuments.us/reader035/viewer/2022062314/56649e225503460f94b0f2b9/html5/thumbnails/16.jpg)
M-16
Staphylococci: Preclinical Summary
No.
Species Category2 Isolates MIC50 MIC90
S. aureus MSSA 916 1.8 2.5
MRSA 973 1.7 3.2
GISA 8 2.0 2.0
S. epidermidis MSSE 183 1.3 2.4
MRSE 216 1.2 2.1
GISE 4 2.0 2.0
Average1
1 Weighted average calculated for pooled studies.2 NCCLS criteria
![Page 17: M-1 Anti-Infective Advisory Committee March 24, 2000 ZYVOX ™ (linezolid) Pharmacia and Upjohn](https://reader035.vdocuments.us/reader035/viewer/2022062314/56649e225503460f94b0f2b9/html5/thumbnails/17.jpg)
M-17
0
20
40
60
80
100
<0.06 0.125 0.25 0.5 1 2 4 8 16 32 >32
Linezolid MIC (µg/mL)
% o
f Iso
late
s
Sentry (N = 4,498)
Phase III (N = 1,370)
Total N = 5,868
S. aureus Sentry and Phase III Data
![Page 18: M-1 Anti-Infective Advisory Committee March 24, 2000 ZYVOX ™ (linezolid) Pharmacia and Upjohn](https://reader035.vdocuments.us/reader035/viewer/2022062314/56649e225503460f94b0f2b9/html5/thumbnails/18.jpg)
M-18
Enterococci: Preclinical Summary
No. Species Category2 Isolates MIC50 MIC90
E. faecalis VSE 476 1.2 2.0
VRE 148 1.7 3.1
E. faecium VSE 68 1.9 2.0
VRE 252 1.3 2.4
Average1
1 Weighted average calculated for pooled studies.2 NCCLS criteria
![Page 19: M-1 Anti-Infective Advisory Committee March 24, 2000 ZYVOX ™ (linezolid) Pharmacia and Upjohn](https://reader035.vdocuments.us/reader035/viewer/2022062314/56649e225503460f94b0f2b9/html5/thumbnails/19.jpg)
M-19
0
20
40
60
80
100
<0.06 0.125 0.25 0.5 1 2 4 8 16 32 >32
Linezolid MIC (µg/mL)
% o
f Iso
late
s
Sentry (N = 1,417)
Phase III (N = 303)
Total N = 1,720
Enterococcus spp Sentry and Phase III Data
![Page 20: M-1 Anti-Infective Advisory Committee March 24, 2000 ZYVOX ™ (linezolid) Pharmacia and Upjohn](https://reader035.vdocuments.us/reader035/viewer/2022062314/56649e225503460f94b0f2b9/html5/thumbnails/20.jpg)
M-20
Laboratory Prediction of Resistance Mechanism
• Low spontaneous mutation frequency– 1 x 10-9
• Inability to derive resistant mutants by– Chemical mutagenesis– Serial passage through 2-fold drug
concentrations
• Spiral-gradient, serial passage yielded two resistant strains– S. aureus– E. faecalis
![Page 21: M-1 Anti-Infective Advisory Committee March 24, 2000 ZYVOX ™ (linezolid) Pharmacia and Upjohn](https://reader035.vdocuments.us/reader035/viewer/2022062314/56649e225503460f94b0f2b9/html5/thumbnails/21.jpg)
M-21
Characterization of Lab-derived Mutants
• Mutations identified in 23S rRNA gene
– S. aureus, G2447U
– E. faecalis, G2576U
• Gene exists in 5-6 copies in Gm+ bacteria
• MIC correlated with ratio of wild-type:mutant genes
• Significant increase in MIC required mutation in at least 2 of 6 gene copies
![Page 22: M-1 Anti-Infective Advisory Committee March 24, 2000 ZYVOX ™ (linezolid) Pharmacia and Upjohn](https://reader035.vdocuments.us/reader035/viewer/2022062314/56649e225503460f94b0f2b9/html5/thumbnails/22.jpg)
M-22
Linezolid Efficaciousin Key Animal Models
• Mouse systemic infection
– Oral, IV, SQ
• Mouse soft tissue infection
• Localized Group A streptococcal myonecrosis
• Pneumococcal pneumonia (neutropenic animals)
• Mouse thigh infection model
![Page 23: M-1 Anti-Infective Advisory Committee March 24, 2000 ZYVOX ™ (linezolid) Pharmacia and Upjohn](https://reader035.vdocuments.us/reader035/viewer/2022062314/56649e225503460f94b0f2b9/html5/thumbnails/23.jpg)
M-23
Summary
• Broad Gm+ coverage
• Lack of inherent cross-resistance with marketed agents
• Therapy will be initiated principally in the hospital or institutional care setting
• Multiple dosage forms, equivalent IV/oral dosing provides treatment flexibility
![Page 24: M-1 Anti-Infective Advisory Committee March 24, 2000 ZYVOX ™ (linezolid) Pharmacia and Upjohn](https://reader035.vdocuments.us/reader035/viewer/2022062314/56649e225503460f94b0f2b9/html5/thumbnails/24.jpg)
M-24
Linezolid - Presentation Agenda
Introduction W. Gary Tarpley, PhDMicrobiology VP, Discovery Research
Clinical Pharmacology Barry Hafkin, MDClinical Trial Results Director, Clinical Research
Early Pediatric Studies Donald Anderson, MD CSO, Research & Development
Conclusion W. Gary Tarpley, PhD
![Page 25: M-1 Anti-Infective Advisory Committee March 24, 2000 ZYVOX ™ (linezolid) Pharmacia and Upjohn](https://reader035.vdocuments.us/reader035/viewer/2022062314/56649e225503460f94b0f2b9/html5/thumbnails/25.jpg)
M-25
Steady-State Plasma Concentrations Linezolid PO 600 mg BID (Mean SD, N=16)
Time After Dose, hours
Pla
sma
Co
nc,
µg/
mL
Staphylococcus
EnterococcusStreptococcus
0 2 4 6 8 10 12
0
4
8
16
20
24
28
12
MIC90
![Page 26: M-1 Anti-Infective Advisory Committee March 24, 2000 ZYVOX ™ (linezolid) Pharmacia and Upjohn](https://reader035.vdocuments.us/reader035/viewer/2022062314/56649e225503460f94b0f2b9/html5/thumbnails/26.jpg)
M-26
Linezolid Absolute Bioavailability After a Single IV or Oral 375 mg Dose (Mean SD, N = 12)
IV (AUC - 50 µg h/mL)
Oral (AUC - 52 µg h/mL)
Time After Dose, Hours
Pla
sma
Co
nc,
µg
/mL
16
12
8
4
00 2 4 6 8 1210
![Page 27: M-1 Anti-Infective Advisory Committee March 24, 2000 ZYVOX ™ (linezolid) Pharmacia and Upjohn](https://reader035.vdocuments.us/reader035/viewer/2022062314/56649e225503460f94b0f2b9/html5/thumbnails/27.jpg)
M-27
Clinical Pharmacology
Oral bioavailibility 100% (based on AUC)
Food effect No effect on AUC Cmax (18%)
Volume of distribution 50 liters
Plasma protein binding 31%
Elimination half-life ~ 6 hours
MAO enzyme Weak, reversible inhibitor
![Page 28: M-1 Anti-Infective Advisory Committee March 24, 2000 ZYVOX ™ (linezolid) Pharmacia and Upjohn](https://reader035.vdocuments.us/reader035/viewer/2022062314/56649e225503460f94b0f2b9/html5/thumbnails/28.jpg)
M-28
Linezolid Metabolism
• Linezolid is not a substrate, inhibitor or inducer of P450
• Two primary metabolites
– Oxidation products of linezolid
![Page 29: M-1 Anti-Infective Advisory Committee March 24, 2000 ZYVOX ™ (linezolid) Pharmacia and Upjohn](https://reader035.vdocuments.us/reader035/viewer/2022062314/56649e225503460f94b0f2b9/html5/thumbnails/29.jpg)
M-29
Linezolid Elimination
• Elimination
~ 35% as parent compound in urine
~ 50% as two primary metabolites in urine
~ 10% as two primary metabolites in feces
• Primary metabolites accumulate in patientswith CLCR30 mL/min
• Linezolid and metabolites are dialyzable
![Page 30: M-1 Anti-Infective Advisory Committee March 24, 2000 ZYVOX ™ (linezolid) Pharmacia and Upjohn](https://reader035.vdocuments.us/reader035/viewer/2022062314/56649e225503460f94b0f2b9/html5/thumbnails/30.jpg)
M-30
Clinical Pharmacology Summary
• No dosage adjustment for
– Route of administration
– Relationship to meals
– Gender or age
– Hepatic or renal impairment
![Page 31: M-1 Anti-Infective Advisory Committee March 24, 2000 ZYVOX ™ (linezolid) Pharmacia and Upjohn](https://reader035.vdocuments.us/reader035/viewer/2022062314/56649e225503460f94b0f2b9/html5/thumbnails/31.jpg)
M-31
Linezolid Efficacy Data
![Page 32: M-1 Anti-Infective Advisory Committee March 24, 2000 ZYVOX ™ (linezolid) Pharmacia and Upjohn](https://reader035.vdocuments.us/reader035/viewer/2022062314/56649e225503460f94b0f2b9/html5/thumbnails/32.jpg)
M-32
Efficacy - Phase III Studies in Adults
55* Complicated 33* Inpatient CAP 31 MRSA
39A* Uncomplicated 51* Outpatient CAP 54A* VRE
48A* HAP
* Pivotal trials
Resistant SST Pneumonia Pathogens
![Page 33: M-1 Anti-Infective Advisory Committee March 24, 2000 ZYVOX ™ (linezolid) Pharmacia and Upjohn](https://reader035.vdocuments.us/reader035/viewer/2022062314/56649e225503460f94b0f2b9/html5/thumbnails/33.jpg)
M-33
Complicated SST (55)
• Randomized, double-blind, equivalence trial
• Dosing regimens:
– Linezolid 600 mg BID IV PO
– Oxacillin 2 g QID IV Dicloxacillin 500 mg QID PO
– Concomitant aztreonam
• Treatment duration: 10-21 days
• Test of cure: 15-21 days PT
• Population: 819 inpatients
![Page 34: M-1 Anti-Infective Advisory Committee March 24, 2000 ZYVOX ™ (linezolid) Pharmacia and Upjohn](https://reader035.vdocuments.us/reader035/viewer/2022062314/56649e225503460f94b0f2b9/html5/thumbnails/34.jpg)
M-34
Clinical Cure Complicated SST (55)
85%91% 90%
77%86% 86%
0%
20%
40%
60%
80%
100%
ITT Clin.Eval. Micro.Eval.
Linezolid Oxacillin/Dicloxacillin
259
300
264
291
95% CI: (2.4, 14.1) (–0.7, 9.5) (–3.5, 11.3)
Missing/Indet: 72 / 65 7 / 2 3 / 0
279328
272354
126140
130151
![Page 35: M-1 Anti-Infective Advisory Committee March 24, 2000 ZYVOX ™ (linezolid) Pharmacia and Upjohn](https://reader035.vdocuments.us/reader035/viewer/2022062314/56649e225503460f94b0f2b9/html5/thumbnails/35.jpg)
M-35
Pathogen Eradication Rates Complicated SST (55)
Linezolid OX/DXPathogen n/N % n/N %
Staphylococcus aureus 85/93 91 87/103 85Streptococcus agalactiae 7/7 100 4/6 67Streptococcus pyogenes 23/29 79 27/32 84Other Streptococcus spp* 10/11 91 5/5 100
* Includes S anginosus, S bovis, S canis, S mitis, and S intermedius
![Page 36: M-1 Anti-Infective Advisory Committee March 24, 2000 ZYVOX ™ (linezolid) Pharmacia and Upjohn](https://reader035.vdocuments.us/reader035/viewer/2022062314/56649e225503460f94b0f2b9/html5/thumbnails/36.jpg)
M-36
Uncomplicated SST (39A)
• Randomized, double-blind equivalence trial• Dosing regimens:
– Linezolid 400 mg BID, PO
– Clarithromycin 250 mg BID, PO
• Treatment duration: 7-14 days
• Test of cure: 7-14 days PT
• Population: 753 outpatients
![Page 37: M-1 Anti-Infective Advisory Committee March 24, 2000 ZYVOX ™ (linezolid) Pharmacia and Upjohn](https://reader035.vdocuments.us/reader035/viewer/2022062314/56649e225503460f94b0f2b9/html5/thumbnails/37.jpg)
M-37
Clinical Cure Uncomplicated SST (39A)
85%91% 88%
83% 87% 87%
0%
20%
40%
60%
80%
100%
ITT Clin.Eval. Micro.Eval.
Linezolid Clarithromycin
262301
283310
95% CI: (–4.0, 7.2) (–0.7, 9.2) (–6.2, 9.3)
Missing/Indet: 39 / 48 4 / 8 1 / 5
290343
268323
126143
122141
![Page 38: M-1 Anti-Infective Advisory Committee March 24, 2000 ZYVOX ™ (linezolid) Pharmacia and Upjohn](https://reader035.vdocuments.us/reader035/viewer/2022062314/56649e225503460f94b0f2b9/html5/thumbnails/38.jpg)
M-38
Pathogen Eradication Rates Uncomplicated SST (39A)
Linezolid ClarithromycinPathogen n/N % n/N %
Staphylococcus aureus 82/91 90 91/108 84Streptococcus agalactiae 10/10 100 4/5 80Streptococcus pyogenes 5/5 100 11/12 92Other Streptococcus spp* 9/10 90 2/3 67
* Includes S anginosus, S canis, and S intermedius, S mitis, and S sanguis
![Page 39: M-1 Anti-Infective Advisory Committee March 24, 2000 ZYVOX ™ (linezolid) Pharmacia and Upjohn](https://reader035.vdocuments.us/reader035/viewer/2022062314/56649e225503460f94b0f2b9/html5/thumbnails/39.jpg)
M-39
Conclusions: SST
Effective in
• Complicated SST
• Uncomplicated SSTdue to
– Staphylococcus aureus
– Streptococcus pyogenes
– Streptococcus agalactiae
![Page 40: M-1 Anti-Infective Advisory Committee March 24, 2000 ZYVOX ™ (linezolid) Pharmacia and Upjohn](https://reader035.vdocuments.us/reader035/viewer/2022062314/56649e225503460f94b0f2b9/html5/thumbnails/40.jpg)
M-40
Efficacy - Phase III Studies in Adults
55* Complicated 33* Inpatient CAP 31 MRSA
39A* Uncomplicated 51* Outpatient CAP 54A* VRE
48A* HAP
* Pivotal trials
Resistant SST Pneumonia Pathogens
![Page 41: M-1 Anti-Infective Advisory Committee March 24, 2000 ZYVOX ™ (linezolid) Pharmacia and Upjohn](https://reader035.vdocuments.us/reader035/viewer/2022062314/56649e225503460f94b0f2b9/html5/thumbnails/41.jpg)
M-41
Patients Hospitalized with CAP (33)
• Randomized, open-label equivalence trial
• Dosing regimens:– Linezolid 600 mg BID, IV PO
Concomitant aztreonam
– Ceftriaxone 1 gm BID, IVCefpodoxime 200 mg BID, PO
• Treatment duration: 7-14 days
• Test of cure: 15-21 days PT
• Population: 747 inpatients
![Page 42: M-1 Anti-Infective Advisory Committee March 24, 2000 ZYVOX ™ (linezolid) Pharmacia and Upjohn](https://reader035.vdocuments.us/reader035/viewer/2022062314/56649e225503460f94b0f2b9/html5/thumbnails/42.jpg)
M-42
Clinical Cure Patients Hospitalized with CAP (33)
83%91% 90%
76%
89% 87%
0%
20%
40%
60%
80%
100%
ITT Clin.Eval. Micro.Eval.
Linezolid Ceftriaxone/cefpodoxime
225254
247272
8193
8089
95% CI: (0.3, 12.8) (–3.0, 7.4) (–6.5, 12.0)
Missing/Indet: 58 / 52 4 / 4 1 / 2
268323
240314
![Page 43: M-1 Anti-Infective Advisory Committee March 24, 2000 ZYVOX ™ (linezolid) Pharmacia and Upjohn](https://reader035.vdocuments.us/reader035/viewer/2022062314/56649e225503460f94b0f2b9/html5/thumbnails/43.jpg)
M-43
Pathogen Eradication Rates Hospitalized CAP (33)
Linezolid CTX/CPDPathogen n/N % n/N %
Streptococcus pneumoniae 63/71 89 62/69 90Staphylococcus aureus 18/20 90 13/17 77
![Page 44: M-1 Anti-Infective Advisory Committee March 24, 2000 ZYVOX ™ (linezolid) Pharmacia and Upjohn](https://reader035.vdocuments.us/reader035/viewer/2022062314/56649e225503460f94b0f2b9/html5/thumbnails/44.jpg)
M-44
Outpatients with CAP (51)
• Randomized, investigator-blind equivalence trial
• Dosing regimens
– Linezolid 600 mg BID, PO
– Cefpodoxime 200 mg BID, PO
• Treatment duration: 10-14 days
• Test of cure: 15-21 days PT
• Population: 540 outpatients
![Page 45: M-1 Anti-Infective Advisory Committee March 24, 2000 ZYVOX ™ (linezolid) Pharmacia and Upjohn](https://reader035.vdocuments.us/reader035/viewer/2022062314/56649e225503460f94b0f2b9/html5/thumbnails/45.jpg)
M-45
Clinical Cure Outpatients with CAP (51)
82%90% 90%86%
91%83%
0%
20%
40%
60%
80%
100%
ITT Clin.Eval. Micro.Eval.
Linezolid Cefpodoxime
185204
182203
3846
4550
95% CI: (–10.3, 3.2) (–6.8, 4.8) (–6.4, 21.1)
Missing/Indet: 45 / 43 4 / 6 1 / 0
188229
191223
![Page 46: M-1 Anti-Infective Advisory Committee March 24, 2000 ZYVOX ™ (linezolid) Pharmacia and Upjohn](https://reader035.vdocuments.us/reader035/viewer/2022062314/56649e225503460f94b0f2b9/html5/thumbnails/46.jpg)
M-46
Pathogen Eradication Rates Outpatient CAP (51)
Linezolid CefpodoximePathogen n/N % n/N %
Streptococcus pneumoniae 25/27 93 19/21 91
Staphylococcus aureus 11/12 92 11/12 92
Haemophilus influenzae 10/12 83 13/15 87
Moraxella catarrhalis 3/3 100 1/1 100
Streptococcus pyogenes 1/1 100 1/1 100
![Page 47: M-1 Anti-Infective Advisory Committee March 24, 2000 ZYVOX ™ (linezolid) Pharmacia and Upjohn](https://reader035.vdocuments.us/reader035/viewer/2022062314/56649e225503460f94b0f2b9/html5/thumbnails/47.jpg)
M-47
Nosocomial Pneumonia (48A)
• Randomized, double-blind equivalence trial
• Dosing regimens:
– Linezolid 600 mg BID, IV
– Vancomycin 1 gm BID, IV
– Concomitant aztreonam
• Treatment duration: 7-21 days
• Test of cure: 15-21 days PT
• Population: 396 inpatientsincluding 229 with ventilator-
associated pneumonia
![Page 48: M-1 Anti-Infective Advisory Committee March 24, 2000 ZYVOX ™ (linezolid) Pharmacia and Upjohn](https://reader035.vdocuments.us/reader035/viewer/2022062314/56649e225503460f94b0f2b9/html5/thumbnails/48.jpg)
M-48
Clinical CureNosocomial Pneumonia (48A)
53%
66% 70%
52%
68% 68%
0%
20%
40%
60%
80%
100%
ITT Clin.Eval. Micro.Eval.
Linezolid Vancomycin
26 38
37 53
62 91
71 107
95% CI: (–10.0, 12.6) (–14.9, 11.3) (–17.9, 20.7)
Missing/Indet: 42 / 51 1 / 5 1 / 2
86 161
74 142
![Page 49: M-1 Anti-Infective Advisory Committee March 24, 2000 ZYVOX ™ (linezolid) Pharmacia and Upjohn](https://reader035.vdocuments.us/reader035/viewer/2022062314/56649e225503460f94b0f2b9/html5/thumbnails/49.jpg)
M-49
Pathogen Eradication Rates Nosocomial Pneumonia (48A)
Linezolid VancomycinPathogen n/N % n/N %
Streptococcus pneumoniae 9/9 100 9/9 100Staphylococcus aureus 25/41 61 15/23 65
![Page 50: M-1 Anti-Infective Advisory Committee March 24, 2000 ZYVOX ™ (linezolid) Pharmacia and Upjohn](https://reader035.vdocuments.us/reader035/viewer/2022062314/56649e225503460f94b0f2b9/html5/thumbnails/50.jpg)
M-50
Conclusions: Pneumonia
Effective in
• Community-acquired pneumonia
• Nosocomial pneumoniadue to
– Streptococcus pneumoniae
– Staphylococcus aureus
![Page 51: M-1 Anti-Infective Advisory Committee March 24, 2000 ZYVOX ™ (linezolid) Pharmacia and Upjohn](https://reader035.vdocuments.us/reader035/viewer/2022062314/56649e225503460f94b0f2b9/html5/thumbnails/51.jpg)
M-51
Efficacy - Phase III Studies in Adults
55* Complicated 33* Inpatient CAP 31 MRSA
39A* Uncomplicated 51* Outpatient CAP 54A* VRE
48A* HAP
* Pivotal trials
Resistant SST Pneumonia Pathogens
![Page 52: M-1 Anti-Infective Advisory Committee March 24, 2000 ZYVOX ™ (linezolid) Pharmacia and Upjohn](https://reader035.vdocuments.us/reader035/viewer/2022062314/56649e225503460f94b0f2b9/html5/thumbnails/52.jpg)
M-52
Methicillin-Resistant Staphylococcus (31)
• Randomized, open-label equivalence trial
• Dosing regimens:
– Linezolid 600 mg BID, IV PO
– Vancomycin 1 gm BID, IV
– Concomitant aztreonam
• Treatment duration: 7-28 days
• Population: 460 patients
![Page 53: M-1 Anti-Infective Advisory Committee March 24, 2000 ZYVOX ™ (linezolid) Pharmacia and Upjohn](https://reader035.vdocuments.us/reader035/viewer/2022062314/56649e225503460f94b0f2b9/html5/thumbnails/53.jpg)
M-53
Primary Source of Infection (31)
Source Patients
SST Infection 230
Pneumonia 99
Bacteremia 50
UTI 27
Other 54
Total 460
![Page 54: M-1 Anti-Infective Advisory Committee March 24, 2000 ZYVOX ™ (linezolid) Pharmacia and Upjohn](https://reader035.vdocuments.us/reader035/viewer/2022062314/56649e225503460f94b0f2b9/html5/thumbnails/54.jpg)
M-54
Clinical Cure - All Patients (31)
57%
77%72%
55%
74% 73%
0%
20%
40%
60%
80%
100%
ITT Clin.Eval. Micro.Eval.
Linezolid Vancomycin
87117
94122
109192
93169
4664
4562
95% CI: (–8.5, 12.0) (–8.2, 13.6) (–16.3, 14.9)Missing/Indet: 48 / 51 2 / 13 0 / 8
![Page 55: M-1 Anti-Infective Advisory Committee March 24, 2000 ZYVOX ™ (linezolid) Pharmacia and Upjohn](https://reader035.vdocuments.us/reader035/viewer/2022062314/56649e225503460f94b0f2b9/html5/thumbnails/55.jpg)
M-55
Clinical Cure - Complicated SST (31)
65%
82% 81%
62%
77% 74%
0%
20%
40%
60%
80%
100%
ITT Clin.Eval. Micro.Eval.
Linezolid Vancomycin
5166
5668
6499
5487
3037
2635
Missing/Indet: 23 / 21 2 / 8 0 / 4
![Page 56: M-1 Anti-Infective Advisory Committee March 24, 2000 ZYVOX ™ (linezolid) Pharmacia and Upjohn](https://reader035.vdocuments.us/reader035/viewer/2022062314/56649e225503460f94b0f2b9/html5/thumbnails/56.jpg)
M-56
Clinical Cure -Nosocomial Pneumonia (31)
51%
77% 75%
50%
74% 75%
0%
20%
40%
60%
80%
100%
ITT Clin.Eval. Micro.Eval.
Linezolid Vancomycin
1419
1722
2039
1632
9 12
1216
Missing/Indet: 11 / 17 0 / 2 0 / 1
![Page 57: M-1 Anti-Infective Advisory Committee March 24, 2000 ZYVOX ™ (linezolid) Pharmacia and Upjohn](https://reader035.vdocuments.us/reader035/viewer/2022062314/56649e225503460f94b0f2b9/html5/thumbnails/57.jpg)
M-57
MRSA Pathogen Eradication (31)
Linezolid Vancomycinn/N % n/N %
ME patients withSST due to MRSA 22/34 65 18/31 58
ME patients with HAP due to MRSA 8/12 67 12/17 71
Total with MRSA 34/56 61 36/57 63
![Page 58: M-1 Anti-Infective Advisory Committee March 24, 2000 ZYVOX ™ (linezolid) Pharmacia and Upjohn](https://reader035.vdocuments.us/reader035/viewer/2022062314/56649e225503460f94b0f2b9/html5/thumbnails/58.jpg)
M-58
VRE Study Design Considerations
• No standard therapy, no acceptable comparators
• Dose-comparison study using 600 mg BID vs 200 mg BID (based on PK and animal models)
• Site of infection: pneumonia, SST, UTI, intra-abdominal infections, bacteremia
![Page 59: M-1 Anti-Infective Advisory Committee March 24, 2000 ZYVOX ™ (linezolid) Pharmacia and Upjohn](https://reader035.vdocuments.us/reader035/viewer/2022062314/56649e225503460f94b0f2b9/html5/thumbnails/59.jpg)
M-59
VRE (54A, 54)
• Randomized, double-blind, superiority trial
• Dosing regimens
– Linezolid 600 mg BID, IV PO
– Linezolid 200 mg BID, IV PO
– Concomitant aztreonam or aminoglycosides
• Treatment duration: 7-28 days
• Population: 54A: 145 patients54: 82 of 186 patients
![Page 60: M-1 Anti-Infective Advisory Committee March 24, 2000 ZYVOX ™ (linezolid) Pharmacia and Upjohn](https://reader035.vdocuments.us/reader035/viewer/2022062314/56649e225503460f94b0f2b9/html5/thumbnails/60.jpg)
M-60
VRE - Primary Infection Source
Bacteremia 20%
Intra-abdominal infections 21%
UTI 37%
SST 18%
Pneumonia 4%
![Page 61: M-1 Anti-Infective Advisory Committee March 24, 2000 ZYVOX ™ (linezolid) Pharmacia and Upjohn](https://reader035.vdocuments.us/reader035/viewer/2022062314/56649e225503460f94b0f2b9/html5/thumbnails/61.jpg)
M-61
Clinical Cure VRE (54A)
67%
89% 86%
54%
74% 76%
0%
20%
40%
60%
80%
100%
ITT Clin.Eval. Micro.Eval.
LZD 600 mg LZD 200 mg
2838
3944
2229
3035
4263
2852
P-values: 0.1609 0.0807 0.3148Missing/Indet: 16 / 14 4 / 2 1 / 0
![Page 62: M-1 Anti-Infective Advisory Committee March 24, 2000 ZYVOX ™ (linezolid) Pharmacia and Upjohn](https://reader035.vdocuments.us/reader035/viewer/2022062314/56649e225503460f94b0f2b9/html5/thumbnails/62.jpg)
M-62
Clinical Cure - Interim Results VRE (54)
62%
75%83%
50%
73%83%
0%
20%
40%
60%
80%
100%
ITT Clin.Eval. Micro.Eval.
LZD 600 mg LZD 200 mg
1622
1824
1518
1518
1829
1836
Missing/Indet: 5 / 12 1 / 3 1 / 1
![Page 63: M-1 Anti-Infective Advisory Committee March 24, 2000 ZYVOX ™ (linezolid) Pharmacia and Upjohn](https://reader035.vdocuments.us/reader035/viewer/2022062314/56649e225503460f94b0f2b9/html5/thumbnails/63.jpg)
M-63
Clinical Cure (CE) by DiagnosisVRE (54A)
Linezolid Linezolid
600 mg BID 200 mg BID
Source of Infection n/N† % n/N† %
Intra-abdominal infections 8/8 100 6/10 60
Bacteremia 9/12 75 3/3 100
UTI 12/13 92 13/19 68
SST 8/9 89 6/6 100
Pneumonia 2/2 100 NA
† Excludes indeterminate and missing.
![Page 64: M-1 Anti-Infective Advisory Committee March 24, 2000 ZYVOX ™ (linezolid) Pharmacia and Upjohn](https://reader035.vdocuments.us/reader035/viewer/2022062314/56649e225503460f94b0f2b9/html5/thumbnails/64.jpg)
M-64
Clinical Cure (CE) by Diagnosis - Interim Results VRE (54)
Linezolid Linezolid
600 mg BID 200 mg BID
Source of Infection n/N† % n/N† %
Intra-abdominal infections 4/5 80 4/5 80
Bacteremia 5/5 100 4/5 80
UTI 8/11 73 6/7 86
SST 1/2 50 2/5 40
Pneumonia 0/1 0 NA† Excludes indeterminate and missing.
![Page 65: M-1 Anti-Infective Advisory Committee March 24, 2000 ZYVOX ™ (linezolid) Pharmacia and Upjohn](https://reader035.vdocuments.us/reader035/viewer/2022062314/56649e225503460f94b0f2b9/html5/thumbnails/65.jpg)
M-65
Microbiologic Outcome (ME) in VRE (54A)
Linezolid Linezolid600 mg BID 200 mg BID
N=36 N=29
Assessment n %† n %†
Microbiological success* 30 86 17 59
Microbiological failure 5 14 12 41
* p=0.0146† Percentages exclude indeterminate and missing.
![Page 66: M-1 Anti-Infective Advisory Committee March 24, 2000 ZYVOX ™ (linezolid) Pharmacia and Upjohn](https://reader035.vdocuments.us/reader035/viewer/2022062314/56649e225503460f94b0f2b9/html5/thumbnails/66.jpg)
M-66
Compassionate Use (25)
• Open-label treatment in patients for whom no alternative was available
• Dosing regimen
– Linezolid 600 mg BID, IV PO
– Concomitant antibiotics were permitted
• Treatment duration: up to 3 months
• Population: 230 patients (30Jun99)
750 patients (01Mar00)
![Page 67: M-1 Anti-Infective Advisory Committee March 24, 2000 ZYVOX ™ (linezolid) Pharmacia and Upjohn](https://reader035.vdocuments.us/reader035/viewer/2022062314/56649e225503460f94b0f2b9/html5/thumbnails/67.jpg)
M-67
Clinical Cure (CE) Compassionate Use (25)
Linezolid
Site of Infection n/N‡ %
Intra-abdominal infections, peritonitis, other 24/26 92
Bacteremia 19/21 90
Complicated SST 7/9 78
Nosocomial pneumonia 1/1 100
UTI 1/1 100
‡ Excludes indeterminate and missing.
![Page 68: M-1 Anti-Infective Advisory Committee March 24, 2000 ZYVOX ™ (linezolid) Pharmacia and Upjohn](https://reader035.vdocuments.us/reader035/viewer/2022062314/56649e225503460f94b0f2b9/html5/thumbnails/68.jpg)
M-68
Conclusions: VRE
• Linezolid 600 mg BID is effective in the treatment of vancomycin-resistant Enterococcus (VRE)
• Clinical and microbiologic outcomes were better in patients randomized to 600 mg BID
• Compassionate use experience supports results in dose-comparative VRE study
![Page 69: M-1 Anti-Infective Advisory Committee March 24, 2000 ZYVOX ™ (linezolid) Pharmacia and Upjohn](https://reader035.vdocuments.us/reader035/viewer/2022062314/56649e225503460f94b0f2b9/html5/thumbnails/69.jpg)
M-69
Efficacy Conclusions
• Linezolid was effective in the treatment of
– Complicated skin and skinstructure infections
– Uncomplicated skin and skinstructure infections
– Community-acquired pneumonia
– Nosocomial pneumonia
– MRSA and VRE infections
![Page 70: M-1 Anti-Infective Advisory Committee March 24, 2000 ZYVOX ™ (linezolid) Pharmacia and Upjohn](https://reader035.vdocuments.us/reader035/viewer/2022062314/56649e225503460f94b0f2b9/html5/thumbnails/70.jpg)
M-70
Resistance Surveillance
• No resistant Staphylococcus or Streptococcus isolates in more than 3,000 patients treated with linezolid in Phase II/III studies
• Resistance developed in 15 of 832 patients treated with linezolid for enterococcal infections in Phase III and compassionate use
![Page 71: M-1 Anti-Infective Advisory Committee March 24, 2000 ZYVOX ™ (linezolid) Pharmacia and Upjohn](https://reader035.vdocuments.us/reader035/viewer/2022062314/56649e225503460f94b0f2b9/html5/thumbnails/71.jpg)
M-71
Resistance Development
ResistantProtocol Patients Enterococcal Isolates
54A 145 1
54 186 5
25 501 9
Probable factors in development of resistance:– Avascular nidus of infection– Extended duration of treatment– Randomized to 200 mg BID
![Page 72: M-1 Anti-Infective Advisory Committee March 24, 2000 ZYVOX ™ (linezolid) Pharmacia and Upjohn](https://reader035.vdocuments.us/reader035/viewer/2022062314/56649e225503460f94b0f2b9/html5/thumbnails/72.jpg)
M-72
Linezolid Safety Data
![Page 73: M-1 Anti-Infective Advisory Committee March 24, 2000 ZYVOX ™ (linezolid) Pharmacia and Upjohn](https://reader035.vdocuments.us/reader035/viewer/2022062314/56649e225503460f94b0f2b9/html5/thumbnails/73.jpg)
M-73
Early Development Issues
• Mild, reversible inhibition of monoamine oxidase (MAO) enzyme
• Mild, transient increases in hepatic enzymes (3- to 5-fold increase in ALT, AST)
• Mild, transient hematopoietic suppression
![Page 74: M-1 Anti-Infective Advisory Committee March 24, 2000 ZYVOX ™ (linezolid) Pharmacia and Upjohn](https://reader035.vdocuments.us/reader035/viewer/2022062314/56649e225503460f94b0f2b9/html5/thumbnails/74.jpg)
M-74
Drug Interactions with MAOIs
• Potent, irreversible MAOIs
– Interaction with serotonergic agents results in serotonin syndrome (cognitive dysfunction, fever, diaphoresis)
– Interaction with adrenergic agents resultsin significant hypertension
• In contrast– Linezolid is a weak, reversible MAOI
![Page 75: M-1 Anti-Infective Advisory Committee March 24, 2000 ZYVOX ™ (linezolid) Pharmacia and Upjohn](https://reader035.vdocuments.us/reader035/viewer/2022062314/56649e225503460f94b0f2b9/html5/thumbnails/75.jpg)
M-75
Phase I MAOI Studies
• Dextromethorphan (serotonergic agent) - no change: body temp, cognitive function, sedation, BP, or pulse
• Tyramine coadministration with LZD required 100 mg to raise SBP by 30 mmHg - no food restrictions
• Blood pressure increases seen with phenylpropanolamine and pseudoephedrine (adrenergic agents) potentiated by LZD coadministration
![Page 76: M-1 Anti-Infective Advisory Committee March 24, 2000 ZYVOX ™ (linezolid) Pharmacia and Upjohn](https://reader035.vdocuments.us/reader035/viewer/2022062314/56649e225503460f94b0f2b9/html5/thumbnails/76.jpg)
M-76
Linezolid - Phenylpropanolamine Systolic BP Effects
Mean Maximum Change Range from Baseline (mmHg) (mmHg)
Placebo 8 7 103-158
Linezolid 11 7 107-135
Phenylpropanolamine 14 11 106-139
Linezolid + Phenylpropanolamine 38 20 129-176
![Page 77: M-1 Anti-Infective Advisory Committee March 24, 2000 ZYVOX ™ (linezolid) Pharmacia and Upjohn](https://reader035.vdocuments.us/reader035/viewer/2022062314/56649e225503460f94b0f2b9/html5/thumbnails/77.jpg)
M-77
Phase II Analysis of PotentialMAOI-Related Drug Interactions
A total of 247 of 867 patients (28%) took potentially interacting drugs
Drug Categories LZD pts with Concomitant Use
sympathomimetic bronchodilators 165
selected analgesics 57
vasopressors 9
cyclic and misc antidepressants 27
indirect-acting sympathomimetics 14
SSRI antidepressants 17
selected antitussive 12
amphetamines and related stimulants 4
serotonin receptor agonists 3
![Page 78: M-1 Anti-Infective Advisory Committee March 24, 2000 ZYVOX ™ (linezolid) Pharmacia and Upjohn](https://reader035.vdocuments.us/reader035/viewer/2022062314/56649e225503460f94b0f2b9/html5/thumbnails/78.jpg)
M-78
Phase II MAOI Experience
• No adverse events attributable tolinezolid MAOI effect
– Food restrictions were lifted for Phase III
– Restrictions regarding potentially MAO interacting drugs were modified
![Page 79: M-1 Anti-Infective Advisory Committee March 24, 2000 ZYVOX ™ (linezolid) Pharmacia and Upjohn](https://reader035.vdocuments.us/reader035/viewer/2022062314/56649e225503460f94b0f2b9/html5/thumbnails/79.jpg)
M-79
Phase III Analysis of PotentialMAOI-Related Drug Interactions
Drug Categories LZD pts with Concomitant Use
sympathomimetic bronchodilators 417
selected analgesics 111
vasopressors 68
cyclic and misc antidepressants 66
indirect-acting sympathomimetics 64
SSRI antidepressants 52
selected antitussive 32
amphetamines and related stimulants 4
serotonin receptor agonists 3A total of 632 of 2046 patients (31%) took potentially interacting drugs
![Page 80: M-1 Anti-Infective Advisory Committee March 24, 2000 ZYVOX ™ (linezolid) Pharmacia and Upjohn](https://reader035.vdocuments.us/reader035/viewer/2022062314/56649e225503460f94b0f2b9/html5/thumbnails/80.jpg)
M-80
Phase III MAOI Experience
• 632 patients were treated with linezolid and potentially interacting drugs
• 13 patients had hypertension as an AE
• In only 1 patient was hypertension judged to be drug-related by the investigator
![Page 81: M-1 Anti-Infective Advisory Committee March 24, 2000 ZYVOX ™ (linezolid) Pharmacia and Upjohn](https://reader035.vdocuments.us/reader035/viewer/2022062314/56649e225503460f94b0f2b9/html5/thumbnails/81.jpg)
M-81
65.0 13.6
Blood Pressure Measurements in Phase III Patients with Concomitant MAOI Potentiators
Pre*MeanSD
Post †
MeanSD Range ‡
(min – max)
Systolic BP (mmHg)
Linezolid 129.9 29.2 130.1 22.8 80 – 184Comparator 127.2 24.4 124.4 23.6 77 – 189
Diastolic BP (mmHg)
Linezolid 66.5 14.9 65.7 12.6 36 – 95Comparator 66.9 13.7 34 – 98
*n = 81 and 93 for linezolid and comparator respectively †n = 76 and 92 for linezolid and comparator respectively‡Ranges of post-dose vital signs
![Page 82: M-1 Anti-Infective Advisory Committee March 24, 2000 ZYVOX ™ (linezolid) Pharmacia and Upjohn](https://reader035.vdocuments.us/reader035/viewer/2022062314/56649e225503460f94b0f2b9/html5/thumbnails/82.jpg)
M-82
MAOI Conclusions
• Preclinical and Phase I
– Weak, reversible MAOI effect
• Phase II and III
– 879 patients received linezolid and a potentially interacting medication
– 1 episode of attributed hypertension
• Benefit vs risk
![Page 83: M-1 Anti-Infective Advisory Committee March 24, 2000 ZYVOX ™ (linezolid) Pharmacia and Upjohn](https://reader035.vdocuments.us/reader035/viewer/2022062314/56649e225503460f94b0f2b9/html5/thumbnails/83.jpg)
M-83
Safety - Phase III Comparator-Controlled Studies
55 Complicated 33 Inpatient CAP 31 MRSA
39A Uncomplicated 51 Outpatient CAP
39 Uncomplicated 48A HAP
Total Patients Treated with Linezolid 2,046
Total Patients Treated with Comparators* 2,001
*vancomycin, ceftriaxone, cefpodoxime, clarithromycin, oxacillin, dicloxacillin
Resistant SST Pneumonia Pathogens
![Page 84: M-1 Anti-Infective Advisory Committee March 24, 2000 ZYVOX ™ (linezolid) Pharmacia and Upjohn](https://reader035.vdocuments.us/reader035/viewer/2022062314/56649e225503460f94b0f2b9/html5/thumbnails/84.jpg)
M-84
All AEs 2% (1 of 2)
Phase III Comparator-Controlled Studies
All Linezolid All ComparatorsN=2046 N=2001
MET n % n %
Diarrhea 170 8.3 126 6.3
Headache 134 6.5 110 5.5
Nausea 127 6.2 92 4.6
Vomiting 75 3.7 41 2.0
Insomnia 52 2.5 35 1.7
![Page 85: M-1 Anti-Infective Advisory Committee March 24, 2000 ZYVOX ™ (linezolid) Pharmacia and Upjohn](https://reader035.vdocuments.us/reader035/viewer/2022062314/56649e225503460f94b0f2b9/html5/thumbnails/85.jpg)
M-85
All AEs 2% (2 of 2)
Phase III Comparator-Controlled Studies
All Linezolid All ComparatorsN=2046 N=2001
MET n % n %
Constipation 44 2.2 42 2.1
Trauma 43 2.1 36 1.8
UTI 43 2.1 27 1.3
Rash 40 2.0 44 2.2
Dizziness 41 2.0 38 1.9
Fever 33 1.6 42 2.1
![Page 86: M-1 Anti-Infective Advisory Committee March 24, 2000 ZYVOX ™ (linezolid) Pharmacia and Upjohn](https://reader035.vdocuments.us/reader035/viewer/2022062314/56649e225503460f94b0f2b9/html5/thumbnails/86.jpg)
M-86
Drug-Related AEs 1% Phase III Comparator-Controlled Studies
All Linezolid All ComparatorsN=2046 N=2001
MET n % n %
Diarrhea 89 4.3 65 3.2
Nausea 69 3.4 46 2.3
Headache 44 2.2 27 1.3
Taste alteration 24 1.2 14 0.7
Vag. moniliasis 24 1.2 13 0.6
Vomiting 23 1.1 8 0.4
Abnormal LFTs 21 1.0 7 0.3
![Page 87: M-1 Anti-Infective Advisory Committee March 24, 2000 ZYVOX ™ (linezolid) Pharmacia and Upjohn](https://reader035.vdocuments.us/reader035/viewer/2022062314/56649e225503460f94b0f2b9/html5/thumbnails/87.jpg)
M-87
Most Common Serious AEs Phase III Comparator-Controlled Studies
All Linezolid All ComparatorsN=2046 N=2001
MET n % n %
Pneumonia 26 1.3 24 1.2
Sepsis 19 0.9 19 0.9
Resp. failure 18 0.9 17 0.8
CHF 11 0.5 8 0.4
Multi-organ failure 10 0.5 8 0.4
Dyspnea 10 0.5 7 0.3
Septic shock 9 0.4 6 0.3
![Page 88: M-1 Anti-Infective Advisory Committee March 24, 2000 ZYVOX ™ (linezolid) Pharmacia and Upjohn](https://reader035.vdocuments.us/reader035/viewer/2022062314/56649e225503460f94b0f2b9/html5/thumbnails/88.jpg)
M-88
Laboratory Assessments
• Mean changes in laboratory assay values
• Substantially abnormal laboratory assay values were assessed by
– Regression analysis
– Hazard function analysis
– Extreme outlier analysis
![Page 89: M-1 Anti-Infective Advisory Committee March 24, 2000 ZYVOX ™ (linezolid) Pharmacia and Upjohn](https://reader035.vdocuments.us/reader035/viewer/2022062314/56649e225503460f94b0f2b9/html5/thumbnails/89.jpg)
M-89
Percent of Patients with Chemistry Assays 2 Times Upper Limit of Normal
All Linezolid All Comparators
Assay n/N % n/N %
ALT (U/L) 145/1959 7.4 139/1919 7.2
AST (U/L) 80/1959 4.1 102/1920 5.3
Creatine kinase (U/L) 103/2017 5.1 65/1976 3.3
Lipase (U/L) 79/2018 3.9 74/1976 3.7
Amylase (U/L) 36/2024 1.8 30/1983 1.5
Total bilirubin (mg/dL) 14/2021 0.7 16/1981 0.8
Studies 31, 33, 39A, 39, 48A, 51, 55
![Page 90: M-1 Anti-Infective Advisory Committee March 24, 2000 ZYVOX ™ (linezolid) Pharmacia and Upjohn](https://reader035.vdocuments.us/reader035/viewer/2022062314/56649e225503460f94b0f2b9/html5/thumbnails/90.jpg)
M-90
Cumulative Percentage Over Time - Patients With at Least One Substantially High ALT Value
0
1
2
3
4
5
6
7
8
9
10
0 2 4 6 8 10 12 14 16 18 20 22 24
Time in Days
Per
cen
t S
ub
stan
tial
ly H
igh
Linezolid Comparators
![Page 91: M-1 Anti-Infective Advisory Committee March 24, 2000 ZYVOX ™ (linezolid) Pharmacia and Upjohn](https://reader035.vdocuments.us/reader035/viewer/2022062314/56649e225503460f94b0f2b9/html5/thumbnails/91.jpg)
M-91
ALT Values for Linezolid-TreatedPatients with Substantially High Values
ALT
(U
/L)
800
700
600
500
400
300
200
100
0Treatment Phase Post Treatment Phase
N=105Mean (SD) Days Trt = 13.35 (4.13)
Analysis Day
Base
2-3
4-5
6-7
8-9
10-11
12-13
>13
1-3P
4-6P
7-9P
10-12P
13-15P16-18P
19-21P
>21P
![Page 92: M-1 Anti-Infective Advisory Committee March 24, 2000 ZYVOX ™ (linezolid) Pharmacia and Upjohn](https://reader035.vdocuments.us/reader035/viewer/2022062314/56649e225503460f94b0f2b9/html5/thumbnails/92.jpg)
M-92
ALT Values for Comparator-TreatedPatients with Substantially High Values
ALT
(U
/L)
800
700
600
500
400
300
200
100
0Treatment Phase Post Treatment Phase
N=98Mean (SD) Days Trt = 13.36 (4.69)
Analysis Day
Base
2-3
4-5
6-7
8-9
10-11
12-13
>13
1-3P
4-6P
7-9P
10-12P
13-15P16-18P
19-21P
>21P
![Page 93: M-1 Anti-Infective Advisory Committee March 24, 2000 ZYVOX ™ (linezolid) Pharmacia and Upjohn](https://reader035.vdocuments.us/reader035/viewer/2022062314/56649e225503460f94b0f2b9/html5/thumbnails/93.jpg)
M-93
Percent of Patients with Hematology Assays < 75% of Lower Limit of Normal*
All Linezolid All Comparators
Studies 31, 33, 39A, 39, 48A, 51, 55* 50% of LLN for neutrophils
Assay n/N % n/N %
Hemoglobin (g/dL) 110/2020 5.4 95/1974 4.8
RBC (x 106/mm3) 83/2019 4.1 73/1973 3.7
Hematocrit (%) 78/2016 3.9 65/1973 3.3
WBC (x 103/mm3) 33/2020 1.6 21/1974 1.1
Neutrophils (x 103/mm3) 15/1954 0.8 17/1909 0.9
Platelets (x 103/mm3) 48/2010 2.4 30/1966 1.5
![Page 94: M-1 Anti-Infective Advisory Committee March 24, 2000 ZYVOX ™ (linezolid) Pharmacia and Upjohn](https://reader035.vdocuments.us/reader035/viewer/2022062314/56649e225503460f94b0f2b9/html5/thumbnails/94.jpg)
M-94
Cumulative Percentage Over Time - Patients With at Least One Substantially Low Platelet Count
0
1
2
3
4
5
6
7
8
9
10
0 2 4 6 8 10 12 14 16 18 20 22 24
Time in Days
Per
cen
t S
ub
stan
tial
ly L
ow
Linezolid Comparators
![Page 95: M-1 Anti-Infective Advisory Committee March 24, 2000 ZYVOX ™ (linezolid) Pharmacia and Upjohn](https://reader035.vdocuments.us/reader035/viewer/2022062314/56649e225503460f94b0f2b9/html5/thumbnails/95.jpg)
M-95
Platelet Counts for Linezolid-TreatedPatients with Substantially Low Values
Treatment Phase Post Treatment Phase
Analysis Day
Base
2-3
4-5
6-7
8-9
10-11
12-13
>13
1-3P
4-6P
7-9P
10-12P
13-15P16-18P
19-21P
>21P
N=27Mean (SD) Days Trt =15.37 (4.49)
1000
900
800
700
600
500
400
300
200
100
0
Pla
tele
t C
ount
(T
hou/
uL)
![Page 96: M-1 Anti-Infective Advisory Committee March 24, 2000 ZYVOX ™ (linezolid) Pharmacia and Upjohn](https://reader035.vdocuments.us/reader035/viewer/2022062314/56649e225503460f94b0f2b9/html5/thumbnails/96.jpg)
M-96
Platelet Counts for Comparator-TreatedPatients with Substantially Low Values
Treatment Phase Post Treatment Phase
Analysis Day
Base
2-3
4-5
6-7
8-9
10-11
12-13
>13
1-3P
4-6P
7-9P
10-12P
13-15P16-18P
19-21P
>21P
N=11Mean (SD) Days Trt =12.18 (2.96)
1000
900
800
700
600
500
400
300
200
100
0
Pla
tele
t C
ount
(T
hou/
uL)
![Page 97: M-1 Anti-Infective Advisory Committee March 24, 2000 ZYVOX ™ (linezolid) Pharmacia and Upjohn](https://reader035.vdocuments.us/reader035/viewer/2022062314/56649e225503460f94b0f2b9/html5/thumbnails/97.jpg)
M-97
Platelet Conclusions
• Risk factors for decreased platelet counts
– Low baseline values
– >2 weeks of therapy
• Decreases are mild and reversible
• Not associated with clinical consequences
![Page 98: M-1 Anti-Infective Advisory Committee March 24, 2000 ZYVOX ™ (linezolid) Pharmacia and Upjohn](https://reader035.vdocuments.us/reader035/viewer/2022062314/56649e225503460f94b0f2b9/html5/thumbnails/98.jpg)
M-98
Safety Conclusions
• Linezolid is well-tolerated in adults treated with 600 mg BID for up to 28 days
• Most common drug-related AEs were diarrhea (4%), nausea (3%), and headache (2%)
• No clear association between adverse events and use of concomitant medications
• Changes in platelet counts were mild and transient
![Page 99: M-1 Anti-Infective Advisory Committee March 24, 2000 ZYVOX ™ (linezolid) Pharmacia and Upjohn](https://reader035.vdocuments.us/reader035/viewer/2022062314/56649e225503460f94b0f2b9/html5/thumbnails/99.jpg)
M-99
Linezolid - Presentation Agenda
Introduction W. Gary Tarpley, PhDMicrobiology VP, Discovery Research
Clinical Pharmacology Barry Hafkin, MDClinical Trial Results Director, Clinical Research
Early Pediatric Studies Donald Anderson, MD CSO, Research & Development
Conclusion W. Gary Tarpley, PhD
![Page 100: M-1 Anti-Infective Advisory Committee March 24, 2000 ZYVOX ™ (linezolid) Pharmacia and Upjohn](https://reader035.vdocuments.us/reader035/viewer/2022062314/56649e225503460f94b0f2b9/html5/thumbnails/100.jpg)
M-100
Linezolid Pediatric Drug Development
• P&U commitment to early pediatric development
• Unmet medical need is equally urgent for children
– PRSP, MRSA, MRSE & VRE are major pathogens in children
– Few safe & effective therapeutic options exist
– Alternative therapeutic agents are needed for serious infections in healthy and high risk pediatric populations, including neonates
![Page 101: M-1 Anti-Infective Advisory Committee March 24, 2000 ZYVOX ™ (linezolid) Pharmacia and Upjohn](https://reader035.vdocuments.us/reader035/viewer/2022062314/56649e225503460f94b0f2b9/html5/thumbnails/101.jpg)
M-101
Linezolid - Pediatric Use Development Program
• Pharmacokinetics (3 mos to 17 yrs)
• PK in neonates - planned
• Safety, Efficacy, PK/PD
• Focus on pneumococcal disease– Community Acquired Pneumonia
– Acute Otitis Media
• Experience with VRE bacteremia
• Currently being planned
Phase II
Phase III
Compassionate Use in Children
Phase I
![Page 102: M-1 Anti-Infective Advisory Committee March 24, 2000 ZYVOX ™ (linezolid) Pharmacia and Upjohn](https://reader035.vdocuments.us/reader035/viewer/2022062314/56649e225503460f94b0f2b9/html5/thumbnails/102.jpg)
M-102
Linezolid - Pediatric Use Clinical Pharmacokinetics
• Clearance adjusted by body weight is inversely proportional to age
• Higher clearance in very young patients; further PK analysis planned for patients < 5 years old
• Children 5 years old given 10 mg/kg oral BID had CL, Vd and t½ at steady state similar to adults
![Page 103: M-1 Anti-Infective Advisory Committee March 24, 2000 ZYVOX ™ (linezolid) Pharmacia and Upjohn](https://reader035.vdocuments.us/reader035/viewer/2022062314/56649e225503460f94b0f2b9/html5/thumbnails/103.jpg)
M-103
Linezolid - Pediatric UsePhase II Study Design
Hospitalized CAP Acute Otitis Media
Study 45, N=78 Study 49, N=65
Age: 12 mos - 17 yrs* 12 mos - 6 yrs
Route: IV, oral oral only
Dose: 10 mg/kg BID 10 mg/kg BID
Duration: 7 - 28 days 7 - 10 days
Design: Open-label, uncontrolled
Safety: AEs, lab assays, vital signs* 95% age 12 mos - 6 yrs
![Page 104: M-1 Anti-Infective Advisory Committee March 24, 2000 ZYVOX ™ (linezolid) Pharmacia and Upjohn](https://reader035.vdocuments.us/reader035/viewer/2022062314/56649e225503460f94b0f2b9/html5/thumbnails/104.jpg)
M-104
Linezolid - Pediatric UseMost Common Drug-Related Adverse Events
Diarrhea 13 9.1
Vomiting 6 4.2
Loose Stools* 5 3.5
Rash 4 2.8
Neutropenia 3 2.1
* Not elsewhere specified
Adverse Event LinezolidMET ITT N=143
n %
![Page 105: M-1 Anti-Infective Advisory Committee March 24, 2000 ZYVOX ™ (linezolid) Pharmacia and Upjohn](https://reader035.vdocuments.us/reader035/viewer/2022062314/56649e225503460f94b0f2b9/html5/thumbnails/105.jpg)
M-105
Linezolid - Pediatric UseAll Reported Serious Adverse Events
Bronchiolitis 1 0.7
Convulsions 1 0.7
Neutropenia 1 0.7
Pneumothorax 1 0.7
Vomiting 1 0.7
Linezolid Adverse Event ITT N=143
MET n %
![Page 106: M-1 Anti-Infective Advisory Committee March 24, 2000 ZYVOX ™ (linezolid) Pharmacia and Upjohn](https://reader035.vdocuments.us/reader035/viewer/2022062314/56649e225503460f94b0f2b9/html5/thumbnails/106.jpg)
M-106
Linezolid - Pediatric UseConclusions
• Safety & efficacy findings in children are promising
• Additional safety and efficacy studies are being planned and implemented, including pivotal studies
• Preliminary pharmacokinetic data suggests a dosing regimen of 10 mg/kg BID for children 5 years old
• More definitive pharmacokinetic studies in neonates and other pediatric age groups are planned or in progress
![Page 107: M-1 Anti-Infective Advisory Committee March 24, 2000 ZYVOX ™ (linezolid) Pharmacia and Upjohn](https://reader035.vdocuments.us/reader035/viewer/2022062314/56649e225503460f94b0f2b9/html5/thumbnails/107.jpg)
M-107
Linezolid - Presentation Agenda
Introduction W. Gary Tarpley, PhDMicrobiology VP, Discovery Research
Clinical Pharmacology Barry Hafkin, MDClinical Trial Results Director, Clinical Research
Early Pediatric Studies Donald Anderson, MD CSO, Research & Development
Conclusion W. Gary Tarpley, PhD
![Page 108: M-1 Anti-Infective Advisory Committee March 24, 2000 ZYVOX ™ (linezolid) Pharmacia and Upjohn](https://reader035.vdocuments.us/reader035/viewer/2022062314/56649e225503460f94b0f2b9/html5/thumbnails/108.jpg)
M-108
Linezolid Conclusions
• Addresses unmet medical need
– Broad Gm+ coverage
• Effective treating Gm+ infections withadded advantages:
– PK profile
– Convenience/flexibility
• Well-tolerated
![Page 109: M-1 Anti-Infective Advisory Committee March 24, 2000 ZYVOX ™ (linezolid) Pharmacia and Upjohn](https://reader035.vdocuments.us/reader035/viewer/2022062314/56649e225503460f94b0f2b9/html5/thumbnails/109.jpg)
M-109
Pharmacia & Upjohn is Seeking Approval of Linezolid for:
• Nosocomial pneumonia
• Community-acquired pneumonia
• Complicated skin and skin structure infections
• Uncomplicated skin and skin structure infections
• Vancomycin-resistant Enterococcus faecalis and Enterococcus faecium infections